Biogen Gains China Approval for At-Home Alzheimer's Treatment
核心洞察
China's National Medical Products Administration (搜索) has approved a self-administered subcutaneous formulation of LEQEMBI for early Alzheimer's disease (搜索), developed by Biogen and partner Eisai.
The new option allows once-weekly at-home dosing via an autoinjector instead of clinic-based infusions, for patients with early-stage Alzheimer's who qualify under the label.
China is only the second country worldwide to clear the at-home subcutaneous version of LEQEMBI, according to Simply Wall St.
Biogen and its partner Eisai have received approval from China's National Medical Products Administration (搜索) for a self-administered subcutaneous formulation of LEQEMBI in early Alzheimer's disease (搜索), according to Simply Wall St on September 16, 2026.
The new LEQEMBI option allows once-weekly at-home subcutaneous dosing via an autoinjector instead of clinic-based infusions, and targets patients with early-stage Alzheimer's who qualify under the product's label. China is only the second country worldwide to clear this at-home subcutaneous version of LEQEMBI.
Biogen shares closed at USD 216.17 on Nasdaq on September 15, 2026, down 0.55% from the prior session, within a 52-week range of USD 135.39 to USD 225.80.
Source: ad-hoc-news.de